Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q2 EPS of ($0.94), $0.07 worse than the analyst estimate of ($0.87). Revenue for the quarter came in at $1 million versus the consensus estimate of $1.1 million.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.